# OnCo record empower-cscc-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/empower-cscc-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "empower-cscc-1", "NCT02760498" ;
  schema:name "EMPOWER-CSCC-1"@en ;
  schema:description "EMPOWER-CSCC-1 showed that cemiplimab shrinks almost half of advanced skin squamous cell cancers, most of them for years, and it gave this cancer its first approved drug."@en ;
  schema:url <https://onco.cc/trials/empower-cscc-1/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02760498>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1805131>, <https://doi.org/10.1136/jitc-2020-002757> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/advanced-cutaneous-scc/>, <https://onco.cc/cancers/cutaneous-scc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/tmb/> .